Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

21. Cognitive training interventions and depression in mild cognitive impairment and dementia: a systematic review and meta-analysis of randomized controlled trials

Cognitive training interventions and depression in mild cognitive impairment and dementia: a systematic review and meta-analysis of randomized controlled trials Cognitive Training Interventions and Depression in Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Age Ageing Actions . 2020 May 6;afaa063. doi: 10.1093/ageing/afaa063. Online ahead of print. Cognitive Training Interventions and Depression in Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , , , , , Affiliations Expand Affiliations 1 Department

2020 EvidenceUpdates

22. Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Netw Open Actions . 2020 Feb 5;3(2):e200075. doi: 10.1001/jamanetworkopen.2020.0075. Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial , , , , Affiliations Expand Affiliations 1 Program on Health, Work and Productivity, Institute for Clinical

2020 EvidenceUpdates

23. Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression after stroke. (Abstract)

Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression after stroke. Depression is an important consequence of stroke that influences recovery yet often is not detected, or is inadequately treated. This is an update and expansion of a Cochrane Review first published in 2004 and previously updated in 2008.The primary objective is to test the hypothesis that pharmacological, psychological therapy, non-invasive brain stimulation, or combinations (...) of these interventions reduce the incidence of diagnosable depression after stroke. Secondary objectives are to test the hypothesis that pharmacological, psychological therapy, non-invasive brain stimulation or combinations of these interventions reduce levels of depressive symptoms and dependency, and improve physical functioning after stroke. We also aim to determine the safety of, and adherence to, the interventions.We searched the Specialised Register of Cochrane Stroke and the Cochrane Depression Anxiety

2020 Cochrane

24. Telephone-based nurse-delivered interpersonal psychotherapy for postpartum depression: nationwide randomised controlled trial Full Text available with Trip Pro

Telephone-based nurse-delivered interpersonal psychotherapy for postpartum depression: nationwide randomised controlled trial Telephone-based Nurse-Delivered Interpersonal Psychotherapy for Postpartum Depression: Nationwide Randomised Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Permalink Copy Page navigation Br J Psychiatry Actions . 2020 Apr;216(4):189-196. doi: 10.1192/bjp.2019.275. Telephone-based Nurse-Delivered Interpersonal Psychotherapy for Postpartum Depression: Nationwide Randomised Controlled Trial , , , , Affiliations Expand Affiliations 1 Professor, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto; Women's Health Research Chair, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada. 2 Associate Professor of Psychiatry, Department

2020 EvidenceUpdates

25. Standardized Library of Depression Outcome Measures

Standardized Library of Depression Outcome Measures Research White Paper Standardized Library of Depression Outcome MeasuresResearch White Paper Standardized Library of Depression Outcome Measures Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2014-00004-C Prepared by: L&M Policy Research, LLC Washington, DC 20009 With partners: OM1, AcademyHealth Investigators: Richard E (...) language for acknowledgment: This work was based on an evidence report, [INSERT TITLE], by the Evidence-based Practice Center Program at the Agency for Healthcare Research and Quality (AHRQ). Suggested citation: Gliklich RE, Leavy MB, Li F. Standardized Library of Depression Outcome Measures. Research White Paper. (Prepared by L&M Policy Research, LLC under Contract No. 290-2014-00004-C.) AHRQ Publication No. 19(20)-EHC005. Rockville, MD: Agency for Healthcare Research and Quality; May 2020. Posted

2020 Effective Health Care Program (AHRQ)

26. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Stay at home Only go outside for food, health reasons (...) or work (but only if you cannot work from home) If you go out, stay 2 metres (6ft) away from other people at all times Wash your hands as soon as you get home Do not meet others, even friends or family. You can spread the virus even if you don’t have symptoms. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids can both cause respiratory depression, which can be fatal if not recognised in time. Only prescribe together

2020 MHRA Drug Safety Update

27. Depression: Perinatal

Depression: Perinatal © 2018 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Perinatal Depression Screening, Diagnosis, and Treatment Guideline Major Changes as of December 2018 2 Target Population 2 Behavioral Health Integration/Maternal Behavioral Health 2 Screening and Diagnosis 3 Treatment Overview of options 5 Shared decision making: pregnant women 7 Key points: breastfeeding women 7 Pharmacologic options 8 Follow-up 10 Evidence Summary 11 References 12 Guideline (...) antidepressant in pregnancy. The first-line antidepressant in both pregnancy and lactation is sertraline and second-line is escitalopram. Fluoxetine is not recommended. Previously, sertraline was first-line and citalopram and fluoxetine were second-line antidepressants for pregnancy and lactation. Escitalopram was not on the preferred list. For pregnant and postpartum women, we now recommend using the Maternal Behavioral Health Screening tool. Previously, depression screening for all adults was done

2020 Kaiser Permanente Clinical Guidelines

28. Treatment of Depression in Children and Adolescents

Treatment of Depression in Children and Adolescents Treatment of Depression in Children and Adolescents: A Systematic Review Comparative Effectiveness Review Number 224 R Comparative Effectiveness Review Number 224 Treatment of Depression in Children and Adolescents: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00011-I Prepared by: RTI (...) and harms of pharmacological and nonpharmacological treatments for child and adolescent depressive disorders. Key Messages • Cognitive behavioral therapy (CBT), fluoxetine, escitalopram, and combined fluoxetine plus CBT may reduce depressive symptoms in the short term; clinical significance is unclear. • CBT may improve symptoms and functional status. CBT plus medications may help prevent relapse. • Selective serotonin reuptake inhibitors (SSRIs) as a class may improve response and functional status

2020 Effective Health Care Program (AHRQ)

29. End-stage Renal Disease and Depression: A Systematic Review

End-stage Renal Disease and Depression: A Systematic Review Management Briefs eBrief-no169 -- End-stage Renal Disease and Depression: A Systematic Review Talk to the Veterans Crisis Line now An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you're connecting (...) to the official website and that any information you provide is encrypted and sent securely. Search Search the ORD website Button to search HSRD Contact us TTY: 711 × We're here anytime, day or night — 24/7 If you are a Veteran in crisis or concerned about one, connect with our caring, qualified responders for confidential help. Many of them are Veterans themselves. Get more resources at . » » » Management Briefs eBrief-no169 -- End-stage Renal Disease and Depression: A Systematic Review Health Services

2020 Veterans Affairs - R&D

30. Vagal nerve stimulation for epilepsy and depression

Vagal nerve stimulation for epilepsy and depression Vagal nerve stimulation for epilepsy and depression | Washington State Health Care Authority Toggle search Toggle navigation Announcement Menu Apple Health Eligibility Manual Search Close menu Search form Search all of HCA Search Health care services and supports Search Billers, providers, & partners Search Employee & retiree benefits Search About HCA Search Vagal nerve stimulation for epilepsy and depression Vagal nerve stimulation (...) for epilepsy and depression Public comment period extended. Public comment on the vagal nerve stimulation draft report has been extended until close of business, March 30, 2020. Submit all comments to: Vagal nerve stimulation (VNS) for epilepsy and depression was first reviewed by the HTA in 2009. In 2013, a review of VNS medical literature was conducted to determine if newly available evidence published since 2008 was likely to change the original coverage determination. The technology was not selected

2020 Washington Health Care Authority

31. But I am not Depressed: Antidepressants for Irritable Bowel Syndrome

But I am not Depressed: Antidepressants for Irritable Bowel Syndrome Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) January 20, 2020 But I am not Depressed: Antidepressants for Irritable Bowel Syndrome Clinical Question: Do antidepressant medications improve irritable bowel syndrome (IBS) symptoms? Bottom Line: Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may improve overall IBS symptoms. About 55% of patients treated with TCAs or SSRIs will benefit compared to ~35% with placebo. Only TCAs improve abdominal pain for ~60% of patients compared to ~30% with placebo. TCA

2020 Tools for Practice

32. Mental Health: Targeted School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms

Mental Health: Targeted School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Mental Health: Targeted School-Based CBT | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) February 2019 Audience Adolescents and Young Adults Children/Infants Setting School (...) Strategy Counseling Health Education Mental Health: Targeted School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Tabs Snapshot Summary of CPSTF Finding The targeted school-based cognitive behavioral therapy programs to reduce depression and anxiety symptoms among school-aged children and adolescents who are assessed to be at increased risk for these conditions. The CPSTF also recommends , and and CBT to reduce psychological harm from traumatic events among

2020 Community Preventive Services Task Force

33. Mental Health: Universal School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms

Mental Health: Universal School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Mental Health: Universal School-Based CBT | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) February 2019 Audience Adolescents and Young Adults Children/Infants Setting School (...) Strategy Counseling Health Education Mental Health: Universal School-Based Cognitive Behavioral Therapy Programs to Reduce Depression and Anxiety Symptoms Tabs Snapshot Summary of CPSTF Finding The universal school-based cognitive behavioral therapy programs to prevent or reduce depression and anxiety symptoms among school-aged children and adolescents. The CPSTF also recommends for students who are assessed to be at increased risk for these conditions, and and CBT to reduce psychological harm from

2020 Community Preventive Services Task Force

34. Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke. (Abstract)

Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke. Depression is an important morbidity associated with stroke that impacts on recovery yet often undetected or inadequately treated. This is an update and expansion of a Cochrane Review first published in 2004 and updated in 2008.Primary objective • To determine whether pharmacological therapy, non-invasive brain stimulation, psychological therapy, or combinations (...) of these interventions reduce the prevalence of diagnosable depression after stroke Secondary objectives • To determine whether pharmacological therapy, non-invasive brain stimulation, psychological therapy, or combinations of these interventions reduce levels of depressive symptoms, improve physical and neurological function and health-related quality of life, and reduce dependency after stroke • To assess the safety of and adherence to such treatments SEARCH METHODS: We searched the Specialised Registers

2020 Cochrane

35. Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study. (Abstract)

Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study. Hong Kong has been embroiled in increasingly violent social unrest since June, 2019. We examined the associated population mental health burden, risk factors, and health-care needs.In a population-based prospective cohort, adult participants aged 18 years or older were assessed at nine timepoints from 2009. Probable depression was measured using the Patient Health Questionnaire-9 (...) (score ≥10) and suspected post-traumatic stress disorder (PTSD) by the PTSD Checklist-Civilian Version (score ≥14), plus direct exposure to traumatic events related to the ongoing social unrest. We used multivariable logistic regression to identify factors associated with both outcomes, adjusting for doctor-diagnosed depression or anxiety disorders before the unrest. On the basis of routine service statistics and respondents' intention to seek professional care, we projected the number of additional

2020 Lancet

36. Esketamine (Spravato) - major depression

Esketamine (Spravato) - major depression Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/578240/2019 EMEA/H/C/004535 Spravato (esketamine) An overview of Spravato and why (...) it is authorised in the EU What is Spravato and what is it used for? Spravato is a medicine used to treat adults with major depression that is resistant to treatment. It is used in combination with an SSRI or SNRI medicine (other antidepressants) when at least two other treatments have failed. Spravato contains the active substance esketamine. How is Spravato used? Spravato is available as a nasal spray to be used by the patient in a clinic or doctor’s office, under the direct supervision of a healthcare

2020 European Medicines Agency - EPARs

37. Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT Full Text available with Trip Pro

Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation (...) or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The research programme has improved our understanding of when patients experience improvement and found that sertraline did not reduce depressive symptoms at 6 weeks but did reduce anxiety symptoms. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & . Larisa Duffy 1, * , Gemma Lewis 1

2020 NIHR HTA programme

38. Guided self-help for depression in autistic adults: the ADEPT feasibility RCT Full Text available with Trip Pro

Guided self-help for depression in autistic adults: the ADEPT feasibility RCT Guided self-help for depression in autistic adults: the ADEPT feasibility RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1

2020 NIHR HTA programme

39. Pharmacy-based management for depression in adults. (Abstract)

Pharmacy-based management for depression in adults. It is common for peoples not to take antidepressant medication as prescribed, with around 50% of people likely to prematurely discontinue taking their medication after six months. Community pharmacists may be well placed to have a role in antidepressant management because of their unique pharmacotherapeutic knowledge and ease of access for people. Pharmacists are in an ideal position to offer proactive interventions to people with depression (...) or depressive symptoms. However, the effectiveness and acceptability of existing pharmacist-based interventions is not yet well understood. The degree to which a pharmacy-based management approach might be beneficial, acceptable to people, and effective as part of the overall management for those with depression is, to date, unclear. A systematic review of randomised controlled trials (RCTs) will help answer these questions and add important knowledge to the currently sparse evidence base.To examine

2019 Cochrane

40. Pharmacological interventions for treatment-resistant depression in adults. (Abstract)

Pharmacological interventions for treatment-resistant depression in adults. Although antidepressants are often a first-line treatment for adults with moderate to severe depression, many people do not respond adequately to medication, and are said to have treatment-resistant depression (TRD). Little evidence exists to inform the most appropriate 'next step' treatment for these people.To assess the effectiveness of standard pharmacological treatments for adults with TRD.We searched the Cochrane (...) Common Mental Disorders Controlled Trials Register (CCMDCTR) (March 2016), CENTRAL, MEDLINE, Embase, PsycINFO and Web of Science (31 December 2018), the World Health Organization trials portal and ClinicalTrials.gov for unpublished and ongoing studies, and screened bibliographies of included studies and relevant systematic reviews without date or language restrictions.Randomised controlled trials (RCTs) with participants aged 18 to 74 years with unipolar depression (based on criteria from DSM-IV-TR

2019 Cochrane